Rigel Pharmaceuticals, Inc. (RIGL) Revenue History
Annual and quarterly revenue from 2013 to 2024
Compound Annual Growth Rate (CAGR)
Loading revenue history...
Revenue Growth Metrics
Revenue Breakdown (FY 2024)
RIGL's revenue distribution by segment and geography for fiscal year 2024
By Product/Segment
RIGL Revenue Analysis (2013–2024)
As of February 28, 2026, Rigel Pharmaceuticals, Inc. (RIGL) generated trailing twelve-month (TTM) revenue of $282.1 million, reflecting exceptional growth of +25.6% year-over-year. The most recent quarter (Q3 2025) recorded $69.5 million in revenue, down 31.7% sequentially.
Looking at the longer-term picture, RIGL's 5-year compound annual growth rate (CAGR) stands at +24.8%, indicating outstanding long-term growth trajectory. The company achieved its highest annual revenue of $179.3 million in 2024, representing a new all-time high.
Revenue diversification analysis shows RIGL's business is primarily driven by Gross product sales (62%), Product sales, net (43%), and Contract revenues from collaborations (10%). With over half of revenue concentrated in Gross product sales, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including ARGX (+335.2% YoY), CANF (-16.0% YoY), and ABVX (+125.1% YoY), RIGL has underperformed the peer group in terms of revenue growth. Compare RIGL vs ARGX →
Peer Comparison
Compare RIGL's revenue metrics with industry peers
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| RIGLCurrent | $282M | +25.6% | +24.8% | 13.5% | |
| ARGX | $2.2B | +335.2% | +94.6% | -1.0% | |
| CANF | $674,000 | -16.0% | -19.8% | -1206.2% | |
| ABVX | $11M | +125.1% | +457.7% | -1602.9% | |
| KYMR | $39M | -16.7% | +2.9% | -891.3% | |
| TGTX | $329M | +31.0% | +364.6% | 12.7% |
Historical Revenue Data
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | $179.3M | +53.4% | $160.6M | 89.6% | $24.2M | 13.5% |
| 2023 | $116.9M | -2.8% | $109.8M | 93.9% | $-20,491,000 | -17.5% |
| 2022 | $120.2M | -19.4% | $118.5M | 98.5% | $-55,550,000 | -46.2% |
| 2021 | $149.2M | +37.4% | $148.2M | 99.3% | $-12,496,000 | -8.4% |
| 2020 | $108.6M | +83.2% | $107.7M | 99.2% | $-28,973,000 | -26.7% |
| 2019 | $59.3M | +33.2% | $58.4M | 98.5% | $-69,091,000 | -116.5% |
| 2018 | $44.5M | +892.6% | $44.2M | 99.4% | $-72,683,000 | -163.3% |
| 2017 | $4.5M | -78.0% | $-41,785,000 | -931.9% | $-79,616,000 | -1775.6% |
| 2016 | $20.4M | -29.5% | $-43,063,000 | -211.3% | $-69,741,000 | -342.2% |
| 2015 | $28.9M | +250.2% | $-33,930,000 | -117.4% | $-51,743,000 | -179.1% |
See RIGL's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs RIGL Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare RIGL vs AGIO
See how RIGL stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is RIGL's revenue growth accelerating or slowing?
RIGL revenue is accelerating at +25.6% year-over-year, exceeding the 5-year CAGR of +24.8%. TTM revenue reached $282M. Growth momentum has increased versus prior periods.
What is RIGL's long-term revenue growth rate?
Rigel Pharmaceuticals, Inc.'s 5-year revenue CAGR of +24.8% reflects the sustained expansion pattern. Current YoY growth of +25.6% is above this long-term average.
How is RIGL's revenue distributed by segment?
RIGL reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2013-2024 are available for download. Segment mix reveals concentration and diversification trends.